GlassScriptPhysician profile
Jarod F Bailey
NPI 1649432733
$3,708.10
in general payments reported to CMS, 2019-2025
30 companies · $1,126 in 2025
The $1,126 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $555 · 2020: $185 · 2021: $588 · 2022: $571 · 2023: $330 · 2024: $352 · 2025: $1,126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,283 · Travel and Lodging: $526.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,282.90 |
| Travel and Lodging | $525.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $714.93 | 2024-2025 | Mako |
| Astellas Pharma US INC | $439.15 | 2019-2025 | Veozah, Myrbetriq |
| Novo Nordisk INC | $350.48 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $294.33 | 2019-2025 | |
| Nevro Corp. | $238.89 | 2022-2024 | Senza |
| Janssen Pharmaceuticals, INC | $214.90 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $207.58 | 2019-2025 | |
| Abbott Laboratories | $198.56 | 2021-2025 | Freestyle Libre, Freestyle Libre 3 |
| Dexcom, INC. | $121.00 | 2021-2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $109.39 | 2022-2024 | |
| Axsome Therapeutics, INC. | $98.61 | 2023-2025 | Auvelity |
| Lilly USA, LLC | $95.56 | 2022-2025 | Zepbound, Jardiance, Amyvid |
| Otsuka America Pharmaceutical, INC. | $84.40 | 2023-2024 | Rexulti |
| Merck Sharp & Dohme LLC | $84.33 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $80.22 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $43.98 | 2021-2023 | |
| Glaxosmithkline, LLC. | $39.13 | 2021-2023 | Arexvy, Shingrix |
| Abbvie INC. | $33.67 | 2021-2023 | Vraylar |
| Seqirus USA INC | $32.33 | 2025 | Fluad, Flucelvax |
| Amgen INC. | $29.42 | 2019-2022 | |
| Shield Therapeutics INC | $29.11 | 2025 | |
| Boston Scientific Corporation | $27.98 | 2025 | Watchman Access System |
| Sunovion Pharmaceuticals INC. | $25.25 | 2022 | |
| Sumitomo Pharma America, INC. | $23.25 | 2023 | Gemtesa |
| Circassia INC. | $19.11 | 2019 | |
| Lundbeck LLC | $18.03 | 2025 | Rexulti |
| Paratek Pharmaceuticals, INC. | $16.20 | 2025 | Nuzyra |
| Ibsa Pharma INC. | $13.56 | 2025 | Tirosint, Licart, Flector |
| Kowa Pharmaceuticals America, INC. | $12.93 | 2019 | |
| Avanir Pharmaceuticals, INC. | $11.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jarod Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.